Clinical usefulness of the SAMe-TT2R2 score:A systematic review and simulation meta-analysis by van Miert, Jasper H A et al.
  
 University of Groningen
Clinical usefulness of the SAMe-TT2R2 score





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Miert, J. H. A., Bos, S., Veeger, N. J. G. M., & Meijer, K. (2018). Clinical usefulness of the SAMe-
TT2R2 score: A systematic review and simulation meta-analysis. PLoS ONE, 13(3), [e0194208].
https://doi.org/10.1371/journal.pone.0194208
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
RESEARCH ARTICLE
Clinical usefulness of the SAMe-TT2R2 score:
A systematic review and simulation meta-
analysis
Jasper H. A. van Miert1*, Sarah Bos2, Nic J. G. M. Veeger3, Karina Meijer1
1 Department of Haematology, University Medical Center Groningen, Groningen, the Netherlands,
2 Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands,




Vitamin K antagonist (VKA) therapy is safer and more effective when patients have a high
time within the therapeutic range and low international normalised ratio variability. The
SAMe-TT2R2 score aims to identify those at risk for poor VKA control.
Objectives
To evaluate the predictive value and clinical usefulness of the SAMe-TT2R2 score to identify
those at risk for poor VKA control.
Methods
We performed a systematic review in MEDLINE and Embase for original research papers
assessing the SAMe-TT2R2’s relation to poor TTR. We performed a meta-analysis where
scores 2 and 3 predicting TTR < 70%. When studies evaluated other cutoffs for TTR or
SAMe-TT2R2, they were harmonised by multiple simulations with patient characteristics
from the individual studies, if the data were available.
Results
16 studies were identified and used in the meta-analysis: 4 and 2 times directly, 8 and 8
times harmonised for scores 2 and 3, respectively (not all studies provided information
about both cutoffs). The sensitivities and specificities were too heterogeneous to pool. The
positive likelihood ratios were 1.25 (1.14-1.38) for a score 2, and 1.24 (1.09-1.40) for a
score 3; the negative ones were 0.87 (0.82-0.93) and 0.96 (0.91-1.02), respectively. This
shows that the post-test probabilities hardly differ from the prior probability (prevalence).
Conclusion
The SAMe-TT2R2 score does predict low TTR, but the effect is small. Its effect on individual
patients is too limited to be clinically useful.
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1 Introduction
Vitamin K antagonist (VKA) therapy is safer and more effective when patients have a high
time within the therapeutic INR range (iTTR) [1] and low INR variability [2, 3]. However, the
quality of anticoagulation achieved differs greatly between individuals. The first period of anti-
coagulant treatment provides some information about future quality [4], but it is unclear how
long this “trial of VKA” should be. Ideally, one could identify patients prone to poor VKA con-
trol before starting treatment. Separate predictors have been identified before, but their combi-
nation was prognostically weak [5–7].
Apostolakis et al. developed a new tool to identify those prone to poor VKA control before
starting treatment: the SAMe-TT2R2 score [8]. The score awards one point each for female sex;
age<60 years; 2 or more of certain comorbidities; and the presence of interacting medication,
and two points each for tobacco use and non-Caucasian race. The score was initially developed
to identify “outliers” (i.e. those below a certain percentile of TTRs) [9, 10]. After further assess-
ment in other studies, it evolved into proposed decision rules to give patients with a score of 2
or higher extra care [11], or suggest that those with a score>2 start a NOAC instead of trying
VKA [12].
While it is not uncommon for a risk score’s area of use to expand, this could jeopardise the
score’s validity. The aim of this tudy is to assess the predictive performance and added clinical
benefit of the SAMe-TT2R2 score, using a systematic review and meta-analysis.
2 Methods
2.1 Selection criteria
Studies were required to meet all the following pre-defined inclusion criteria for the systematic
review:
• Participants: patients on VKA, naive or experienced
• Test: SAMe-TT2R2 score
• Outcome: quality of anticoagulation (time in therapeutic range [13] or percentage of inter-
national normalised ratios in therapeutic range (PINRR); both henceforth called “TTR” for
brevity)
• Type of study: published original research paper
The studies were required to provide data to derive or calculate test statistics (such as pre-
dictive values and likelihood ratios) from a 2x2 contingency table for inclusion in our meta-
analysis.
2.2 Data sources and searches
We searched MEDLINE and Embase and included studies indexed up to 12 January 2017, the
date of our last search. We used the search term SAMe-TT2R2, without limits on language or
otherwise. We excluded MEDLINE citations in Embase. We checked references of the included
studies.
2.3 Study selection
Two independent reviewers (JvM and SB) performed the study selection individually based on
the predefined inclusion and exclusion criteria. They screened all titles and abstracts of the
articles to identify potentially eligible studies. The full text of these potentially eligible studies
was then evaluated to determine eligibility for the systematic review and meta-analysis.
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Disagreements were resolved through discussion. There were no unresolved disagreements
among the reviewers, which needed the advice of a third reviewer. When multiple studies were
conducted on the same population of patients, we would extract data from the most complete
publication or combine the results. The Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement for reporting of systematic reviews and meta-analyses of
randomised clinical trials was followed [14]. The PRISMA flowchart in Fig 1 shows the selec-
tion process; the PRISMA checklist is included in S1 Supporting Information. The study was
not prospectively registered.
2.4 Data collection process
Two reviewers extracted data from each article independently (JvM and SB). Discrepancies
between the reviewers were resolved by consensus. The following data were extracted from the
included trials: indication for anticoagulation therapy, quality of anticoagulation achieved and
its measurement method, numbers of patients, TTR cutoffs, SAMe-TT2R2 cutoffs, and test
Fig 1. PRISMA flowchart [14] detailing the search strategy used.
https://doi.org/10.1371/journal.pone.0194208.g001
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specifics. When the SAMe-TT2R2 cutoffs used in the study differed from those we chose, we
modelled the different cutoffs if possible (see below).
2.5 Quality assessment
We rated the overall quality of evidence using the revised Tool for the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2 [15]; see S2 Table). Agreement on the quality of the
individual studies was obtained after discussion (JvM and SB). If information to score a partic-
ular part of the assessment tool was absent we defined this risk of bias as unclear. Risk of bias
of the index test was defined as unclear whenever SAMe-TT2R2 of 2 or 3 was not used as a
cutoff to predict poor anticoagulation. We visually inspected funnel plots and performed a
mixed-effects meta-regression model to assess possible publication bias.
2.6 Data synthesis
2.6.1 Test statistics from original studies. We analysed SAMe-TT2R2 cutoffs of2 and
3 (following from the aforementioned decision rules) to predict a TTR <70% (a TTR below
the benchmark for high quality anticoagulation [11]). From articles that used the same TTR
cutoff, we derived test statistics from the 2x2 contingency table (we algebraically calculated
one based on information from the text when the contingency table was unavailable) with a
spreadsheet tool [16].
2.6.2 Harmonising cutoffs using a simulation. When a different TTR cutoff was used,
we gathered the mean and standard deviation for each SAMe-TT2R2 category. This allowed us
to simulate a TTR for every subject by sampling from a beta distribution set up to mimic a
truncated normal distribution (because TTR is always between 0 and 100%). We created a 2x2
contingency table using cutoffs for TTR and SAMe-TT2R2, and used this to calculate test statis-
tics. Every study was simulated thousand times, to incorporate the sampling uncertainty.
These simulations were performed in R (R Foundation for Statistical Computing, Vienna,
Austria) on Windows, using a script that is available as a supplement.
2.7 Data analysis
To assess the performance of our simulation, we simulated all studies with their original cutoff
values, and compared the simulated test statistics with those originally found in the article.
We presumed heterogeneity in studies as a result of variation in VKA control achieved in
different settings by different clinics, and indication for treatment. We pooled data using a ran-
dom effects model, unless the outcomes were too heterogeneous in effect sizes (based on the
forest plots) or had a too large I2. Likelihood ratios, negative and positive predictive values,
sensitivity, specificity, and power of separation (difference between the post-test probabilities
of the two groups [17]) are reported.
The meta-analysis was performed in R using the metafor package [18]. We report data as
point estimate (95% confidence or reference interval) unless otherwise indicated.
3 Results
3.1 Study selection
We identified 57 distinct articles. We excluded 41 records, so 16 studies [8, 19–33] could be
included in the systematic review and meta-analysis (see S1 Supporting Information).
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3.2 Study characteristics
14 studies [8, 19–21, 23–26, 28–33] were performed in patients with atrial fibrillation; 2 [22,
27] were done in patients with venous thromboembolism. 5 studies [19, 22, 27, 29, 31]
reported on VKA naive patients; 5 [23–25, 32, 33] on experienced patients and for 6 [8, 20, 21,
26, 28, 30] this was not reported. Study characteristics are summarised in Table 1.
16 different studies were included in the meta-analysis: 12 for a SAMe-TT2R2 cutoff of 2,
10 for a cutoff 3. 8 and 8 studies were simulated before inclusion, respectively.
3.3 Quality assessment
The risk of systematic bias within studies was low. However, the specific methodology of many
studies was unclear. Some studies provided insufficient data on patient selection; many studies
did not provide enough information about the timing of the calculation of the SAMe-TT2R2
score and quality of anticoagulation. This could introduce survival bias: patients with poor
VKA control may cease treatment. Multiple studies did not evaluate a cutoff for the SAMe-
TT2R2 score or the TTR, but chose to evaluate the variables continuously. The quality assess-
ment is summarised in S1 Table.
Due to the limited number of studies for each combination of score and TTR cutoffs, we
could not assess publication bias for every combination. For those combinations where it was
possible, we found no evidence for publication bias.
Table 1. Study characteristics.
Study Score TTR Ind N Cohort Period excluded TTR duration TTR method
Abumuaileq [19]  2 < 70 AF 911 inception first month 12 months or until event PINRR
Abumuaileq [19]  2 < 65 AF 911 inception first month 12 months or until event PINRR
Apostolakis [8] – – AF 286 not reported not reported not reported Rosendaal
Bernaitis [20] – – AF 1137 not reported not reported not reported Rosendaal
Chan [21] > 2 > 70 AF 1428 not reported first 6 weeks not reported Rosendaal
Chan [21] > 3 > 70 AF 1428 not reported first 6 weeks not reported Rosendaal
Demelo [22]  2 < 65 VTE 135 inception first month not reported Rosendaal
Gallego [23] – – AF 972 experienced none 6 months Rosendaal
Gorzelak [24] – – AF 104 experienced none 6 months back Rosendaal
Lip [25] – – AF 229 experienced not reported not reported Rosendaal
Lobos [26]  2 < 65 AF 1524 not reported not reported 12 months back Rosendaal
Lobos [26]  2 < 70 AF 1524 not reported not reported 12 months back Rosendaal
Lobos [26]  3 < 65 AF 1524 not reported not reported 12 months back Rosendaal
Palareti [27]  2 < 65 VTE 1308 inception not reported not reported Rosendaal
Park [28] – – AF 380 not reported first month not reported Rosendaal
Poli [29] – – AF 1089 inception none not reported Rosendaal
Proietti [30] > 2 < 70 AF 3624 mixed mixed not reported Rosendaal
Proietti [30] > 2 < 65 AF 3624 mixed mixed not reported Rosendaal
Roldan [31]  2 < 65 AF 459 inception not reported 6 months Rosendaal
Ruiz [32] < 2 > 65 AF 1056 experienced not reported 6 months back Rosendaal
Ruiz [32] < 2 > 70 AF 1056 experienced not reported 6 months back Rosendaal
Szymanski [33] – – AF 211 experienced not reported not reported Rosendaal
AF: Atrial fibrillation; Ind: indication; N: number of patients included; period excluded: period excluded in calculation of the TTR; Score: SAMe-TT2R2 score; TTR: time
in therapeutic range (here also percentage of INR’s in therapeutic range); VTE: venous thromboembolism
https://doi.org/10.1371/journal.pone.0194208.t001
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3.4 Results of individual studies
The articles used myriad ways to evaluate the SAMe-TT2R2 score: some authors used a high
score to predict low TTR [8, 19, 22, 26, 27, 30–32], others a low score to predict high TTR [21,
32]. This affects the sensitivity and specificity. The cutoffs used to define a “high” score or a
“low” TTR varied as well. Some studies evaluated multiple cutoffs for quality of anticoagulation
or SAMe-TT2R2 [19, 21, 26, 30, 32]. The SAMe-TT2R2 cutoff 2 in combination with a TTR
cutoff of 65 was studied most often: in 6 studies [19, 22, 26, 27, 31, 32] including 5393 patients.
6 studies [8, 20, 23–25, 29] were performed without cutoffs for SAMe-TT2R2 score or TTR,
including 3817 patients. The results of the individual studies (recalculated to have a SAMe-
TT2R2 cutoff predict a TTR < cutoff) are summarised in S2 Table.
The prevalence of TTR below the cutoff was 39–89%. The prevalence of a SAMe-TT2R2
score above the cutoff was 21–46% and 5–82% in studies that evaluated cutoffs 2 and 3,
respectively. Sensitivity and specificity ranged from 6–82% and 14–96%, respectively. 4 studies
[21, 22, 28, 33] showed that a high score made poor anticoagulation less likely (LR+ < 1).
There were no patients with a SAMe-TT2R2 score < 2 in three Asian studies [20, 21, 28],
because the SAMe-TT2R2 score awards two points for non-Caucasian race. Another study’s
[30] results could not be used for the simulation, so only the original cutoff could be used.
Therefore, these studies could only be used to assess the score’s performance with a cutoff 3.
Other studies only reported dichotomised SAMe-TT2R2 scores with a cutoff of 2 [22, 24–26,
31, 33]. These studies were excluded for the evaluation of the cutoff 3. From the study that
introduced the SAMe-TT2R2 score [8], we only used the external validation cohort.
3.5 Validation of the simulation
We simulated all studies with their original cutoff values and compared the simulated point
estimates and boundaries of the reference interval with their counterparts found in the studies.
We did this for sensitivity, specificity, positive and negative predictive values, and prevalence
of low TTR. This is graphically shown in Fig 2. Pearson’s correlation was 99%. The simulated
point estimate fell in the original confidence interval in 82% of cases, and the differences
between the original and simulated point estimates were small: mean< 0.01, SD = 0.03 (see
also S1 Fig).
3.6 Meta-analysis
The results of the meta-analysis are summarised in Table 2, Fig 3 and S2 Fig. We decided not
to pool the data for sensitivities and specificities, because they were too heterogeneous (see Fig
3; lower bound of 95% CI of I2 >97%).
Fig 2. Calibration plot comparing simulated values with the corresponding values from the original studies.
https://doi.org/10.1371/journal.pone.0194208.g002
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Table 2. Performance of the SAMe-TT2R2 score to predict TTR<70%.
SAMe-TT2R2 LR- LR+ PSEP
 2 0.87 (0.82–0.93) 1.25 (1.14–1.38) 0.08 (0.05–0.11)
 3 0.96 (0.91–1.02) 1.24 (1.09–1.40) 0.06 (0.02–0.10)
LR-, LR+: negative and positive likelihood ratio, respectively; PSEP: power of separation; TTR: time in therapeutic
range
https://doi.org/10.1371/journal.pone.0194208.t002
Fig 3. Forest plots showing positive and negative likelihood ratios (LR+, LR-) of the SAMe-TT2R2 score, using cutoffs of2 and3 to predict a
TTR<70%.
https://doi.org/10.1371/journal.pone.0194208.g003
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4 Discussion
Vitamin K antagonist (VKA) therapy is safer and more effective when patients have a high
time within the therapeutic INR range (iTTR) [1] and low INR variability [2, 3]. The SAMe-
TT2R2 score [8] was developed to identify VKA control outliers before they started treat-
ment. While the score has been adopted in AF guidelines [1], the added benefit of this score
remains unclear. We evaluated how well the score identified those with a poor TTR (< 70%,
which is below the European Society of Cardiology’s cutoff for high-quality anticoagulation
[11]) with cutoffs from proposed decision rules [11, 12], using a systematic review and meta-
analysis.
There is a striking difference in how studies applied and validated the SAMe-TT2R2 score.
This process, from identifying those with poorest VKA control [8, 10] to evaluating the rela-
tionship with continuous [19, 20, 23] or categorised TTR values [21, 27, 28, 31, 32], fits the
exploration of the score’s usefulness for individual patient care. This heterogeneity is however
confusing, which is why we harmonised the different cutoffs. We evaluated SAMe-TT2R2 cut-
offs of 2 (“patients who might need extra care” [11]) and 3 (“should start a direct oral
anticoagulation instead of VKA” [12]).
The score’s sensitivity and specificity to identify a TTR <70% differed substantially between
studies. A more consistent finding was that a test outcome does not decrease the uncertainty
about VKA control substantially: the prior and posterior probabilities hardly differ (0.08
(0.05–0.11) and 0.06 (0.02–0.10) for cutoffs 2 and 3, respectively). This is also reflected in the
likelihood ratios (LR+ 1.25 (1.14–1.38) and 1.24 (1.09–1.40); LR- 0.87 (0.82–0.93) and 0.96
(0.91–1.02)), which are very close to unity and graphically shown in Fig 4.
More important for clinical practice is whether a test manages to make the post-test
probability surpass a clinical probability threshold: from a “grey area” of clinical uncer-
tainty, to the certainty treatment is (un)necessary. It is unlikely that the SAMe-TT2R2
score is able to do this: the change in probabilities is too small. The pre-test probability of a
poor TTR varies from setting to setting (e.g. by country, or with manual versus computer-
assisted dosing). An estimate of this probability can be based on the TTRs achieved by other
patients managed in a particular setting. In the Netherlands patients are managed by dedi-
cated thrombosis services that publish statistics on the TTRs of their patients in their annual
reports.
The other way around, one could ask the question in which populations the score could
change clinical decision making. This depends on the clinical probability thresholds used.
Imagine one wants to be 70% certain of poor VKA control before withholding VKA therapy,
and will definitely start VKA therapy if the probability of poor TTR is less than 20%. A
score 2 is only useful when the prior probability is between 65.1% (lowest prior probability
which will result in a post probability  70%) and 69.9% (if the prior probability already
equals the threshold, we do not need additional information). Likewise, a score < 2 is only
useful for prior probabilities 20.1–22.2%. For a score cutoff of 3, these numbers are 65.3–
69.9% and 20.1–20.6%, respectively. This underlines the limited clinical usefulness from the
score.
Others have tried to predict an individual’s TTR. Rose et al. developed a more extensive
prediction model, but its explained variation was low (3.2–6.8%) [5]. The same is true for the
work of MacEdo et al. (7% variation explained) [6]. Mueller et al. [7] did not report the vari-
ance in TTR explained by the HAS-BLED score, but we estimated it with a simulation to be
around 12%. Even pharmacogenetics-based warfarin dosing only moderately improved TTR
[34]. This shows that there is a large unexplained inter-individual difference in the response to
VKA.
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4.1 Strengths and limitations
Our study has strengths and limitations. The studies we identified were heterogeneous in
many aspects: the cutoffs used for the SAMe-TT2R2 score and TTR, the method to determine
quality of anticoagulation, and the indication for anticoagulation therapy.
We used a simulation method to uniform the cutoffs and calculate their outcomes. This is a
not yet established method, but we have shown this works very well. It allowed us to meta-ana-
lyse the results with established methods.
There was one study that did not report the TTR with the Rosendaal method, but instead
counted the number of INR measurements within range. The two methods are not equivalent
[35]. Sensitivity analysis showed the results did not change meaningfully when only studies
using the Rosendaal method were included (see S3 Fig and S3 Table).
There was no difference in the score’s performance in patients with atrial fibrillation, com-
pared with those with venous thromboembolism (S3 Fig and S3 Table). The assumption that
the SAMe-TT2R2 score performs best in populations with a high probability of a low TTR and
a large spread in TTRs could not be substantiated in post-hoc sensitivity analyses (S3 Fig and
S3 Table).
Fig 4. Pre-test and post-test probabilities plot for the possible SAMe-TT2R2 scores. Results from individual studies are indicated
by dots, with the horizontal and vertical lines representing the 95% confidence interval.
https://doi.org/10.1371/journal.pone.0194208.g004
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Many studies conclude that the SAMe-TT2R2 score performs well based on a statistically
significant C statistic or statistically significant differences in mean TTR between SAMe-
TT2R2 groups. To answer our question, we evaluated different outcomes. Post-test probabili-
ties of certain cutoffs (in this case SAMe-TT2R2 score2 and3) are relevant for clinical deci-
sion making. The C statistic summarises the performance of all possible cutoffs, and is more
appropriate when no cutoffs have been defined. Furthermore, it assesses the probability of a
certain test outcome given the presence or absence of disease, instead of the probability of
poor TTR given a certain SAMe-TT2R2. A different mean TTR in SAMe-TT2R2 groups does
not address the score’s discriminatory performance; there may be considerable overlap.
4.2 Conclusion
The SAMe-TT2R2 score does predict low TTR, but the effect is small. Its effect on individual
patients is too limited to be clinically useful. Therefore, the evidence does not support the use
of the aforementioned decision rules.
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